Thursday, November 12, 2026

Copper Bullish Momentum: 0.3% Up Since The Last Session

ViaNews Editorial Team

January 6, 2021

Copper Bullish Momentum: 0.3% Up Since The Last Session

Copper is currently on bullish momentum. At 19:00 EST on Tuesday, 5 January, Copper is at $3.65 and 0.3% up since the last session's close.

Copper Range

Copper is 2.657% up from its last session low of $3.56 and 2.384% up from its last session high of $3.57.

Copper is 2.38% up from its last three sessions higher value of $3.57 and is 4.14% up from its last three sessions lower value of $3.51.

Copper is 2.00% up from its last seven sessions higher value of $3.58 and is 4.14% up from its last seven sessions lower value of $3.51.

Copper is 0.14% up from its last month's higher value of $3.65 and is 4.51% up from its last month's lower value of $3.49.

Volatility

Copper's last day, last week, and last month's average volatility was 1.39%, 0.14%, and 0.27%, respectively.

Copper's last day, last week, and last month's high and low average amplitude percentage was 0.27%, 0.55%, and 0.63%, respectively.

Last news about Copper

Surge copper appoints leif nilsson as chief executive officer. According to Business Insider on Monday, 4 January, "VANCOUVER, BC, Jan. 4, 2021 /CNW/ - Surge Copper Corp. (TSXV: SURG) ("Surge" or the "Company") is pleased to announce the appointment of Leif Nilsson as Chief Executive Officer of Surge. ", "The Company owns a 100% interest in the Ootsa Property, an advanced stage exploration project containing the East Seel, West Seel and Ox porphyry deposits located adjacent to the open pit Huckleberry Copper Mine, owned by Imperial Metals. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com